• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of xcience and technology policy >4 The Incentives Issue
【24h】

4 The Incentives Issue

机译：4激励问题

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Opponents of any government involvement with the negotiations of prices for biomedical products express the concerns that the negotiated prices would lessen the incentives for biomedical companies to invest in R&D and reduce biomedical innovation. Those concerns may also be expressed about our proposal for government royalties to be introduced subsequently. In this section, we address the incentives issue and explain the circumstances for which appropriate incentives for R&D remain despite our proposed royalties to the government from the sales of biomedical products supported through either of the avenues delivering public funding for the development of the products. Our proposal to return royalties (beyond those generated by the negotiated terms for licenses for federal laboratory patented inventions such as the paclitaxel-eluting stent) would be likely to lower effective prices paid by the taxpayers. Our proposed policy could take the place of negotiated prices, although, as we shall explain, if used as a complementary policy, both it and a negotiated price policy would be more effective.
机译：反对任何政府的参与为生物医学产品价格谈判表达了担忧,协商价格会减少生物医学的激励公司投资于研发和减少生物医学创新。关于我们的提议政府版税随后介绍了。解决激励问题和解释情况下,适当的激励研发仍然尽管我们提议版税政府从生物医学的销售产品支持通过的途径提供发展的公共资金这些产品。(除了那些生成的谈判条件为联邦实验室的专利许可发明如紫杉醇洗脱支架)价格可能会降低有效纳税人。谈判价格,虽然,我们必须去解释,如果用作补充政策,它和协商价格政策将会更多有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号